H.C. Wainwright raised the firm’s price target on Anixa Biosciences to $12 from $11 and keeps a Buy rating on the shares post the fiscal Q1 results.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on ANIX:
- Anixa Biosciences reassures shareholders it has no accounts at SVB
- Anixa Biosciences issued NoA from USPTO for breast cancer vaccine technology
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue